rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Aldeyra Therapeutics, Inc.

ALDX · Nasdaq

Health CareBiotechnologyNot moving yet

ALDX stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 58.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 32
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$1.0M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
102 (-16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.6M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Todd C. BradyPresident and CEObought250,000at $1.673 Jun 2026filed 5 Jun 2026
Richard DouglasDirectorbought70,000at $1.4019 Mar 2026filed 20 Mar 2026
Michael AlfieriPrincipal Financial Officerbought5,000at $1.4218 Mar 2026filed 19 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders102-16 on the quarter
New · exited20 · 36
Reported value$74.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Knoll Capital Management, LLCunchanged · filed 14 Aug 20265,475,516$11.7M00.0%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20263,751,558$8.0M+921,683+32.6%
KINGDON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 20262,652,315$5.6M+500,000+23.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20262,361,796$5.0M-1,946−0.1%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20261,940,338$4.1M+536,348+38.2%
MARSHALL WACE, LLPadded · filed 13 Aug 20261,506,974$3.2M+1,377,281+1062.0%
683 Capital Management, LLCreduced · filed 14 Aug 20261,450,000$3.1M-50,000−3.3%
JANE STREET GROUP, LLCadded · filed 14 Aug 20261,375,115$2.9M+406,224+41.9%
BlackRock, Inc.reduced · filed 7 Aug 20261,257,243$2.7M-2,506,644−66.6%
Qube Research & Technologies Ltdadded · filed 14 Aug 20261,128,803$2.4M+1,041,725+1196.3%
31 Mar 2023 – 30 Jun 2026
88108127Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Ben Bronstein Company insiderDirector · last 9 Jun 20263 · 0
Darlene M. Deptula-Hicks Company insiderDirector · last 9 Jun 20260 · 0
Gary M. Phillips Company insiderDirector · last 9 Jun 20261 · 0
Nancy Miller-Rich Company insiderDirector · last 9 Jun 20262 · 0
Neal Walker Company insiderDirector · last 9 Jun 20261 · 0
Richard Douglas Company insiderDirector · last 9 Jun 20268 · 0
William D. Clark Company insiderDirector · last 9 Jun 20260 · 0
Todd C. Brady Company insiderPresident and CEO · last 3 Jun 202614 · 2
Michael Alfieri Company insiderPrincipal Financial Officer · last 18 Mar 20262 · 0
Stephen Machatha Company insiderChief Development Officer · last 11 Aug 20250 · 5
Martin Joseph Joyce Company insiderDirector · last 10 Jun 20255 · 0
Perceptive Life Sciences Master Fund Ltd Company insider10% owner · last 3 Apr 202512 · 3

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-79.7%
Debt to equityFY 2025 · to 31 Dec 20250.69×
Share count trendFY 2025 · to 27 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$70.0M

Analyst forecasts

No analyst forecasts yet.